Locations:
SearchAdvertisement
Retrospective study yields clues to understanding risk of secondary myeloid neoplasms
New BMT leadership looks to clinical research and cell therapy production to overcome treatment access limitations
Pilot Study at Cleveland Clinic is Testing Feasibility and Biodistribution
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Breaking through barriers in cancer care
Findings support need for personalized disease management
Pathogenic POLE/POLD1 mutations lead to improved response to immune checkpoint blockade therapy
The decision to use 223-radium, and an outcome that exceeded expectations
Tumor genomics offer clues for identifying high risk of relapse
High-quality programs help ensure that screening – now considered standard of care – is done right
Advertisement
Advertisement
